CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Advantages of Off-the-Shelf CAR NK Therapy in B-Cell Malignancies

May 1st 2020

Bob Valamehr, PhD, chief development officer at Fate Therapeutics, discusses the advantages of off-the-shelf CAR NK therapy in B-cell malignancies.

Positive Safety Profile Reported for Atezolizumab/Axi-Cel Combo in DLBCL

April 29th 2020

A manageable safety profile was observed for the combination of atezolizumab and the anti-CD19 chimeric antigen receptor T-cell therapy, axicabtagene ciloleucel, in patients with refractory diffuse large B-cell lymphoma.

Universal Allogeneic CAR T-Cell Product Demonstrates Efficacy in a Cohort of Adult T-ALL

April 29th 2020

The first-in-clinic universal CAR T-cell therapy TruUCAR GC027 induced promising early response rates and demonstrated a manageable safety profile with no evidence of neurotoxicity events or graft-versus-host disease in adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia.

Bispecific CD19/CD22 CAR T Cells Active in Pediatric Relapsed ALL

April 28th 2020

Treatment with CD19/22 chimeric antigen receptor CAR T cells induced a promising response in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Novel Off-the-Shelf CAR-NK Therapy FT596 Shows Early Promise in B-Cell Malignancies

April 22nd 2020

Bob Valamehr, PhD, discusses the process by which a targeted CAR natural-killer cell product is engineered as well as how it will be examined in future research efforts.

CD19 CAR T-Cell Therapy Shows Efficacy in Real-World Setting

April 22nd 2020

Investigators at Montefiore showed that axicabtagene-ciloleucel can be used successfully in ethnically diverse patients with high-risk, relapsed/refractory diffuse large B-cell lymphoma at an inner-city hospital.

FDA Grants RMAT Designation to Tisagenlecleucel for Follicular Lymphoma

April 22nd 2020

The FDA has granted a Regenerative Medicine Advanced Therapy designation to tisagenlecleucel for the treatment of patients with relapsed/refractory follicular lymphoma.

Electronic Tools Enhance Documentation of Patients on CAR T-Cell Therapy

April 17th 2020

Dylan Essner, discusses the utility of novel electronic documentation tools developed by technicians at Epic Beacon, among others, in the documentation, grading, and treatment of patients receiving CAR T-cell therapy.

Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: What's on the Horizon for CAR T-Cell Therapies

April 17th 2020

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, June 2, 2020 at 8 PM EST.

Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: Mitigation and Management of Adverse Events

April 16th 2020

CAR T-Cell Therapy During the COVID-19 Pandemic: A Closer Look at Real-World Data

April 16th 2020

CAR T-Cell Therapy During the COVID-19 Pandemic: A Closer Look at Real-World Data

April 16th 2020

Dr. Park on Ongoing Research Efforts With CAR T-Cell Therapies in ALL

April 2nd 2020

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.

Dr. Awan on Novel Strategies Under Exploration in Relapsed/Refractory CLL

April 2nd 2020

Farrukh Awan, MD, discusses novel approaches under investigation in relapsed/refractory chronic lymphocytic leukemia.

Dr. Levine on Programmed Anticancer Immunity With T-cell and NK-cell Therapies

March 31st 2020

Bruce L. Levine, PhD, discusses engineered anticancer immunity with T-cell and natural killer–cell therapies.

Dr. Berdeja on Updated Data With bb21217 in Multiple Myeloma

March 31st 2020

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses updated data with bb21217 in multiple myeloma.

Outpatient CAR T-Cell Therapy Found Safe, Effective in Large B-Cell Lymphoma

March 30th 2020

Carlos R. Bachier, MD, discusses the use of CAR T-cell therapy in the outpatient setting. He also shared insight on the evolving paradigm of graft-versus-host disease.

Optimal Management Needed for Blood Count Recovery Following CAR T-Cell Therapy

March 27th 2020

Tania Jain, MBBS, discusses blood count recovery in patients with hematology malignancies who receive CAR T-cell therapy.

Community Oncologist Discusses CAR T-Cell Therapy and Other Hematology Advances

March 27th 2020

Sameer Desai, MD, discusses his experience in the hematology field and how CAR T-cell therapy has evolved and its potential integration into community centers.

Expert Highlights Contributing Elements to Hemopoietic Recovery From CAR T-Cell Therapy

March 26th 2020

Craig Sauter, MD, discusses results of a retrospective, real-world review of patients with hematologic malignancies who developed cytopenia post-CAR T-cell therapy.